Intervacc AB (ST:IVACC) — Market Cap & Net Worth
Market Cap & Net Worth: Intervacc AB (IVACC)
Intervacc AB (ST:IVACC) has a market capitalization of $47.68 Million (Skr443.06 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #22148 globally and #417 in its home market, demonstrating a 2.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intervacc AB's stock price Skr1.30 by its total outstanding shares 340813188 (340.81 Million). Review Intervacc AB debt and liabilities to assess the company's total debt and financial obligations.
Intervacc AB Market Cap History: 2017 to 2026
Intervacc AB's market capitalization history from 2017 to 2026. Data shows change from $278.74 Million to $47.68 Million (-17.58% CAGR).
Index Memberships
Intervacc AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.84 Billion | 0.30% | #68 of 281 |
Weight: Intervacc AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Intervacc AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intervacc AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.64x
Intervacc AB's market cap is 3.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $278.74 Million | $48.00 Million | -$12.77 Million | 5.81x | N/A |
| 2018 | $245.74 Million | $35.60 Million | -$27.49 Million | 6.90x | N/A |
| 2019 | $662.02 Million | $12.14 Million | -$27.89 Million | 54.54x | N/A |
| 2020 | $1.94 Billion | $4.78 Million | -$25.60 Million | 405.13x | N/A |
| 2021 | $1.95 Billion | $5.24 Million | -$29.38 Million | 372.30x | N/A |
| 2022 | $953.60 Million | $9.68 Million | -$64.16 Million | 98.47x | N/A |
| 2023 | $232.17 Million | $8.02 Million | -$102.85 Million | 28.97x | N/A |
| 2024 | $42.91 Million | $11.79 Million | -$75.52 Million | 3.64x | N/A |
Competitor Companies of IVACC by Market Capitalization
Companies near Intervacc AB in the global market cap rankings as of June 19, 2026.
Key companies related to Intervacc AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Intervacc AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Intervacc AB's market cap moved from $278.74 Million to $ 47.68 Million, with a yearly change of -17.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr47.68 Million | +40.69% |
| 2025 | Skr33.89 Million | -21.03% |
| 2024 | Skr42.91 Million | -81.52% |
| 2023 | Skr232.17 Million | -75.65% |
| 2022 | Skr953.60 Million | -51.13% |
| 2021 | Skr1.95 Billion | +0.76% |
| 2020 | Skr1.94 Billion | +192.52% |
| 2019 | Skr662.02 Million | +169.40% |
| 2018 | Skr245.74 Million | -11.84% |
| 2017 | Skr278.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Intervacc AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.68 Million USD |
| MoneyControl | $47.68 Million USD |
| MarketWatch | $47.68 Million USD |
| marketcap.company | $47.68 Million USD |
| Reuters | $47.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more